We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Assay Rapidly Identifies Lethal Pathogen Responsible for Clostridium difficile Infection
Product News

New Assay Rapidly Identifies Lethal Pathogen Responsible for Clostridium difficile Infection

New Assay Rapidly Identifies Lethal Pathogen Responsible for Clostridium difficile Infection
Product News

New Assay Rapidly Identifies Lethal Pathogen Responsible for Clostridium difficile Infection


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New Assay Rapidly Identifies Lethal Pathogen Responsible for Clostridium difficile Infection"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced that it obtained CE Marking of the BD MAX™ Cdiff Assay. The assay detects the toxin B gene (tcdB), which has been shown to be present in all toxigenic C. difficile and is essential for disease.

Run on the fully automated BD MAX™ System, the assay is designed to rapidly and accurately identify patients with Clostridium difficile infection (CDI), including those caused by hypervirulent strains. Rapidly and accurately identifying these patients enables appropriate treatment and infection control measures to be implemented quickly, which may improve patient outcomes.

“As CDI rates continue to increase in healthcare facilities worldwide, rapid molecular testing for detection of toxigenic C. difficile can help expedite appropriate treatment, reduce length of stay, and improve patient outcomes,” said Tom Polen, President, BD Diagnostics – Diagnostic Systems.  “The BD MAX Cdiff Assay launch is another important milestone in our effort to deliver a range of clinical tests on the BD MAX System, offering laboratories improved efficiency, turnaround time, and productivity.”

According to a recent study in the American Journal of Infection Control, nucleic acid amplification tests provide better sensitivity over enzyme immunoassay and glutamate dehydrogenase testing algorithms for detection of toxigenic C. difficile.  C. difficile is a gram-positive bacterium that is responsible for the development of antibiotic-associated diarrhea and colitis that can progress to toxic megacolon, sepsis and death.  More than 95 percent of antibiotic-associated pseudomembranous colitis cases are caused by CDIs, resulting in more than $1 billion in healthcare costs annually.

Advertisement